8-K/A: Cabaletta Bio Announces Positive Clinical Data Updates for Rese-cel Across Multiple Autoimmune Indications

Cabaletta Bio reports deepening clinical responses with its rese-cel therapy in SLE, LN, and dermatomyositis patients, with many discontinuing immunosuppressants and steroids.

Summary

• Cabaletta Bio announced updated clinical data from the first 10 patients dosed with resecabtagene autoleucel (rese-cel) across the RESET clinical development program.
• The data, presented at scientific meetings, showed deepening clinical efficacy over time.
• Three SLE patients achieved DORIS remission, the first LN patient achieved complete renal response, and the first dermatomyositis patient maintained a major TIS improvement.
• These patients discontinued all immunosuppressants and are off or tapering steroids.
• The safety profile continues to suggest a favorable risk-benefit ratio, with 90% of patients experiencing either no CRS or Grade 1 CRS and 90% experiencing no ICANS.
• Deep B cell depletion was observed in all patients after rese-cel infusion, with a transitional nave B cell phenotype upon repopulation.
• Tissue-resident B cell elimination was confirmed by a lymph node biopsy in a scleroderma patient.
• As of February 13, 2025, 26 patients have been enrolled across the RESET clinical development program at 50 clinical sites in the U.S. and Europe.
• The company intends to meet with the FDA in the first half of 2025 to align on registrational trial designs.
• Since November, the company has been enrolling an average of one patient per week.

Sentiment

Score: 8

Explanation: The document presents positive clinical data and a clear path forward, suggesting a favorable outlook for the company and its rese-cel therapy.

Positives

• Deepening clinical responses observed in multiple autoimmune indications.
• Patients are able to discontinue immunosuppressants and steroids.
• Favorable safety profile with low rates of CRS and ICANS.
• Deep B cell depletion and subsequent repopulation with a nave phenotype.
• Increasing enrollment rate in the RESET program.
• The first adult dermatomyositis patient maintained a major total improvement score (TIS) improvement at 3 months post-infusion.
• In the RESET-SLE trial, 3 out of 4 patients in the non-renal systemic lupus erythematosus (SLE) cohort achieved DORIS (definition of remission in SLE) remission as of the most recent follow-up visit.
• The first patient dosed with rese-cel in the lupus nephritis (LN) cohort achieved a complete renal response (CRR).

Risks

• The long-term durability of the clinical responses is still uncertain.
• The small sample size of the initial data may not be representative of the broader patient population.
• Regulatory approval is not guaranteed, and the FDA may require additional data.
• Unexpected safety or efficacy data observed during clinical studies could impact the program.
• Volatile market and economic conditions and public health crises could impact the program.

Future Outlook

Cabaletta Bio plans to meet with the FDA in the first half of 2025 to align on registrational trial designs and expects to generate sufficient data this year to further clarify rese-cel's profile across multiple indications.

Management Comments

• David J. Chang, M.D., Chief Medical Officer, stated that rese-cel has the potential to transform the lives of patients with autoimmune disease.
• Management believes its expanding footprint of clinical sites in the US and Europe has facilitated its ability to accelerate the pace of enrollment and dosing across the RESET program.

Industry Context

The announcement highlights the growing interest in CAR T-cell therapies for autoimmune diseases, positioning Cabaletta Bio as a key player in this emerging field. Other companies are also exploring CAR T-cell therapies for autoimmune diseases, such as Novartis and Cartesian Therapeutics, but Cabaletta is focused on B cell mediated autoimmunity.

Comparison to Industry Standards

• The clinical results reported by Cabaletta Bio are promising compared to standard treatments for autoimmune diseases, which often involve chronic immunosuppression.
• Companies like Bristol Myers Squibb (Orencia) and Roche (Rituxan) offer treatments that manage symptoms but do not offer a potential cure.
• Cabaletta's approach of using CAR T-cell therapy to reset the immune system is similar to strategies being explored in oncology, but with modifications to target autoimmune-specific pathways.
• The DORIS remission rates in SLE and complete renal response in LN are encouraging when compared to traditional therapies, which often struggle to achieve these endpoints.

Stakeholder Impact

• Positive impact on patients with autoimmune diseases who may benefit from a potential curative therapy.
• Potential positive impact on shareholders due to the promising clinical data.
• Potential positive impact on employees due to the company's progress and growth.

Next Steps

• Meet with the FDA to align on registrational trial designs in the first half of 2025.
• Continue enrolling patients in the RESET clinical development program.
• Generate sufficient data to further clarify rese-cel's profile across multiple indications this year.

Key Dates